Search Within

Joachim Yahalom

  1. "Craig Moskowitz"
Formats
  1. Meeting Abstract (47)
  2. Journal Article (40)
Groups
  1. Department of Medicine (87)
  2. Hematologic Malignancies, Division of (87)
  3. Radiation Oncology, Department of (87)
  4. Survivorship Research (87)
  5. Center for Hematologic Malignancies (71)
  6. Lymphoma (71)

More Groups

People
  1. Craig Moskowitz (87)
  2. Andrew Zelenetz (62)
  3. David Straus (37)
  4. Carol Portlock (34)
  5. Ariela Noy (32)
  6. Paul Hamlin (26)

More People

Years
  1. 2023 (1)
  2. 2021 (2)
  3. 2020 (2)
  4. 2019 (1)
  5. 2018 (4)
  6. 2017 (8)

More Years

Publications
  1. Blood (37)
  2. International Journal of Radiation Oncology, Biology, Physics (9)
  3. Journal of Clinical Oncology (8)
  4. British Journal of Haematology (7)
  5. Journal of the National Comprehensive Cancer Network (5)
  6. Haematologica (4)

More Publications

Publishers
  1. American Society of Hematology (38)
  2. Elsevier Inc. (11)
  3. American Society of Clinical Oncology (8)
  4. John Wiley & Sons (7)
  5. Harborside Press (5)
  6. Ferrata Storti Foundation (4)

More Publishers

Results (87)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Early toxicities associated with radiation based conditioning for relapsed/refractory Hodgkin lymphoma patients undergoing high dose therapy and autologous stem cell transplantation (HDT-ASCT)
    Meeting Abstract

    Shah, G. L.; Scordo, M.; Devlin, S. M.; Yahalom, J.; Matasar, M. J.; Moskowitz, A.; Giralt, S. A.; Moskowitz, C. H.
    Biology of Blood and Marrow Transplantation (2017)

    Fulltext@MSK | Save
  • A pilot study of brentuximab vedotin and AVD chemotherapy followed by 20 Gy involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma
    Meeting Abstract

    Kumar, A.; Casulo, C.; Advani, R. H.; Budde, L.; Barr, P. M.; Batlevi, C. L.; Caron, P.; Chen, R. W.; Constine, L. S.; Courtien, A.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma
    Journal Article

    Moskowitz, A. J.; Schöder, H.; Gavane, S.; Thoren, K. L.; Fleisher, M.; Yahalom, J.; McCall, S. J.; Cadzin, B. R.; Fox, S. Y.; Gerecitano, J.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • A pilot study of brentuximab vedotin and AVD chemotherapy followed by 20 Gy involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma
    Meeting Abstract

    Kumar, A.; Casulo, C.; Advani, R.; Budde, E.; Barr, P. M.; Batlevi, C. L.; Chen, R.; Constine, L. S.; Courtien, A. I.; Dandapani, S. V.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save
  • Dose and/or volume reduction using consolidation volume radiation therapy (CVRT) lowers dose to heart and lungs in early-stage Hodgkin lymphoma patients with bulky disease
    Meeting Abstract

    Yang, J. C.; Kumar, A.; Chapman, K. L.; Burleson, S.; Huang, C.; Constine, L. S.; Hoppe, R. T.; Dandapani, S.; Straus, D. J.; Moskowitz, C. H.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save
  • Baseline metabolic tumor volume is an independent prognostic factor for relapsed and refractory Hodgkin lymphoma patients receiving PET-adapted salvage therapy with brentuximab vedotin and augmented ICE
    Meeting Abstract

    Moskowitz, A. J.; Schöder, H.; Gavane, S.; Thoren, K. L.; Fleisher, M.; Yahalom, J.; McCall, S. J.; Fox, S. Y.; Gerecitano, J.; Grewal, R.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save
  • Hodgkin lymphoma version 1.2017, NCCN Clinical Practice Guidelines in Oncology
    Journal Article

    Hoppe, R. T.; Advani, R. H.; Ai, W. Z.; Ambinder, R. F.; Aoun, P.; Bello, C. M.; Benitez, C. M.; Bernat, K.; Bierman, P. J.; Blum, K. A.; more...
    Journal of the National Comprehensive Cancer Network (2017)

    Fulltext@MSK | Save
  • Accelerated total lymphoid irradiation-containing salvage regimen for patients with refractory and relapsed Hodgkin lymphoma: 20 years of experience
    Journal Article

    Rimner, A.; Lovie, S.; Hsu, M.; Chelius, M.; Zhang, Z.; Chau, K.; Moskowitz, A. J.; Matasar, M.; Moskowitz, C. H.; Yahalom, J.
    International Journal of Radiation Oncology, Biology, Physics (2017)

    Fulltext@MSK | Save
  • PET-adapted therapy with brentuximab vedotin and augmented ICE for relapsed/refractory Hodgkin lymphoma - Lack of Improvement with 3 versus 2 cycles of weekly brentuximab vedotin
    Meeting Abstract

    Moskowitz, A. J.; Schöder, H.; Yahalom, J.; McCall, S. J.; Fox, S. Y.; Gerecitano, J.; Grewal, R.; Hamlin, P. A.; Horwitz, S.; Kobos, R.; more...
    Haematologica (2016)

    Fulltext@MSK | Save
  • Brentuximab vedotin and AVD chemotherapy followed by ISRT: A safe primary treatment regimen for early-stage, unfavorable Hodgkin lymphoma
    Meeting Abstract

    Yang, J. C.; Kumar, A.; Chapman, K. L.; Constine, L. S.; Moskowitz, C. H.; Yahalom, J.
    International Journal of Radiation Oncology, Biology, Physics (2016)

    Fulltext@MSK | Save